Shareholder Update Regarding Capsalus Revenue Reporting Delay on Fiscal 2011 10-K Annual Report

Capsalus Corp. (OTCBB: WELL and, temporarily, OTCBB: WELLE), today announced that the necessary revenue numbers for its fourth quarter are not yet available to include in its Fiscal 2011 10-K annual report for the fiscal year ending Dec. 31, 2011 due to a required change in GeneLink Biosciences, Inc. (OTCBB: GNLK) auditors.

On Feb. 16, Capsalus had announced the completed acquisition of the stock of GeneWize Life Sciences, Inc., the wholly-owned direct-selling subsidiary of GeneLink Biosciences, a leader in consumer genomics. The deal provided immediate revenues.

Due to the unavailability of the fourth quarter audited financials, an "E" symbol was placed on Capsalus’ ticker symbol by the OTC Bulletin Board, informing the company that it had 30 days to file the annual report. Capsalus is actively working with the new auditors at GeneLink to have the "E" symbol removed as quickly as possible.

For more information about Capsalus, visit www.capsalus.com or call 888-400-7179.

Capsalus Corp. (www.capsalus.com) partners with and acquires visionary enterprises in the health and wellness space producing progressive, broad-based solutions for better physical, nutritional and emotional health worldwide. Capsalus, which derives its name from “Salus,” the Roman goddess of health and prosperity, works with companies in varying stages of development, from consumer products to media and technology and biotechnology. It provides operating infrastructure, strategic pathways and financial support to get them to the mass market quickly and efficiently.

GeneWize Life Sciences, Inc. (www.genewize.com) is a beauty and wellness network marketing DNA customized nutritional supplements, skin care and gene modulating weight management products through self-directed businesses. Its LifeMap Nutrition System™, Healthy Aging Assessment™ and LifeMap Skin Care System™ offer a revolutionary new scientific approach to delivering formulations that truly address individual needs based on a consumer’s personal genetic assessment. GeneWize is committed to delivering the highest quality, scientifically proven health, beauty and wellness products. The company’s mission is to empower individuals to take personal responsibility and control of their health.

Forward-looking Statements

This news release may contain “Forward-looking Statements” within the meaning of Section 21E of the United States Securities Exchange Act, as amended. All statements in this news release, other than statements of historical fact, are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. This notice expressly qualifies all forward-looking statements in this news release.

GeneLink (CE) (USOTC:GNLKQ)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025